Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.42 |
| ▸ | CKS1B | P61024 | 5/20 | 0.39 |
| ▸ | SKP1 | P63208 | 5/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 5/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25027553 | 0.83 | HTR2A (0.42) | PIM2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15401407 | 0.81 | CKS1B (0.59) | CKS1BSKP1SKP2ALDH1A1GBA1 | |
| SCHEMBL15400478 | 0.80 | GRIN2D (0.43) | PIM2CKS1BSKP1SKP2HCAR2 | |
| SCHEMBL418886 | 0.79 | HTR2A (0.42) | PIM2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL20460055 | 0.77 | PIM2 (0.33) | PIM2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2320635 | 0.76 | ROCK2 (0.37) | CKS1BSKP1SKP2ALDH1A1GBA1 | |
| SCHEMBL3267279 | 0.76 | KDM4E (0.57) | CKS1BSKP1SKP2KDM4EALDH1A1 | |
| SCHEMBL5233265 | 0.74 | AKR1C3 (0.61) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1432688 | 0.74 | CKS1B (0.56) | CKS1BSKP1SKP2ALDH1A1GBA1 | |
| SCHEMBL440473 | 0.73 | GRIN2D (0.48) | KDM4EALDH1A1HPGDHSD17B10SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | GENENTECH,INC. | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM2 3/4885CKS1B 177/4885SKP1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.